Efficacy and safety of setipiprant in seasonal allergic rhinitis: Results from Phase 2 and Phase 3 randomized, double-blind, placebo- and active-referenced studies

Allergy, Asthma and Clinical Immunology

Volumn 13, Issue 1, 2017, Pages

  Ratner, Paul ^a   Andrews, Charles P ^b   Hampel, Frank C ^c   Martin, Bruce ^d   Mohar, Dale E ^e   Bourrelly, Denis ^f   Danaietash, Parisa ^f   Mangialaio, Sara ^f   Dingemanse, Jasper ^f   Hmissi, Abdel ^f   Bavel, Jay ^g  

^a Sylvana Research Associates   (United States)

^b Diagnostics Research Group   (United States)

^c Central Texas Health Research   (United States)

^d Southwest Allergy and Asthma Research   (United States)

^e Kerrville Research Associates   (United States)

^f ACTELION PHARMACEUTICALS LTD   (Switzerland)

^g Isis Clinical Research LLC   (United States)

Author keywords

Allergy; Efficacy; Mountain Cedar pollen; Rhinitis; Safety; Setipiprant

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; CETIRIZINE; PLACEBO; SETIPIPRANT;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; BRONCHITIS; CONTROLLED STUDY; DAYTIME EYE SYMPTOM SCORE; DAYTIME NASAL SYMPTOM SCORE; DISEASE ASSESSMENT; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EARDRUM PERFORATION; ECG ABNORMALITY; FEMALE; HUMAN; HYPERTRANSAMINASEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NIGHT TIME NASAL SYMPTOM SCORE; OUTCOME ASSESSMENT; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POLLEN ALLERGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SINUSITIS; TREATMENT DURATION; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA;

EID: 85016987831     PISSN: 17101484     EISSN: 17101492     Source Type: Journal    
DOI: 10.1186/s13223-017-0183-z     Document Type: Article

References (46)

1. Licari A, Ciprandi G, Marseglia A, Castagnoli R, Barberi S, Caimmi S, Marseglia GL. Current recommendations and emerging options for the treatment of allergic rhinitis. Exp Rev Clin Immunol. 2014;10:1337-47.
2. Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, van Wijk RG, Ohta K, Zuberbier T, Schunemann HJ. Allergic rhinitis and its impact on asthma (aria) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126:466-76.
3. Scadding GK, Williams A. The burden of allergic rhinitis as reported by uk patients compared with their doctors. Rhinology. 2008;46:99-106.
4. Laforest L, Bousquet J, Pietri G, Sazonov Kocevar V, Yin D, Pacheco Y, Van Ganse E. Quality of life during pollen season in patients with seasonal allergic rhinitis with or without asthma. Int Arch Allergy Immunol. 2005;136:281-6.
5. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, Zuberbier T, Baena-Cagnani CE, Canonica GW, van Weel C, et al. Allergic rhinitis and its impact on asthma (aria) 2008 update (in collaboration with the world health organization, ga(2)len and allergen). Allergy. 2008;63:8-160.
6. Scadding GK. Hay fever and asthma: are we failing our patients? Drugs Today. 2008;44(Suppl B):19-24.
7. Keith PK, Desrosiers M, Laister T, Schellenberg RR, Waserman S. The burden of allergic rhinitis (AR) in Canada: perspectives of physicians and patients. Allergy Asthma Clin Immunol. 2012;8(1):7.
8. Marple BF, Fornadley JA, Patel AA, Fineman SM, Fromer L, Krouse JH, Lanier BQ, Penna P, American Academy of Otolaryngic Allergy Working Group on Allergic Rhinitis. Keys to successful management of patients with allergic rhinitis: focus on patient confidence, compliance, and satisfaction. JAMA Otolaryngol Head Neck Surg. 2007;136:S107-24.
9. Benninger M, Farrar JR, Blaiss M, Chipps B, Ferguson B, Krouse J, Marple B, Storms W, Kaliner M. Evaluating approved medications to treat allergic rhinitis in the united states: an evidence-based review of efficacy for nasal symptoms by class. Ann Allergy Asthma Immunol. 2010;104:13-29.
10. Scadding GK, Durham SR, Mirakian R, Jones NS, Leech SC, Farooque S, Ryan D, Walker SM, Clark AT, Dixon TA, et al. BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin Exp Allergy. 2008;38:19-42.
11. Wallace DV, Dykewicz MS, Bernstein DI, Blessing-Moore J, Cox L, Khan DA, Lang DM, Nicklas RA, Oppenheimer J, Portnoy JM, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008;122:S1-84.
12. Blaiss MS. Safety considerations of intranasal corticosteroids for the treatment of allergic rhinitis. Allergy Asthma Proc. 2007;28:145-52.
13. Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ. 1998;317:1624-9.
14. Castillo J, Dimov V. Investigational drugs for the treatment of allergic rhinitis. Expert Opin Invest Drugs. 2014;23:823-36.
15. Mandhane SN, Shah JH, Thennati R. Allergic rhinitis: an update on disease, present treatments and future prospects. Int Immunopharmacol. 2011;11:1646-62.
16. Kostenis E, Ulven T. Emerging roles of DP and CRTH2 in allergic inflammation. Trends Mol Med. 2006;12:148-58.
17. Pettipher R, Hansel TT, Armer R. Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nature Rev Drug Discov. 2007;6:313-25.
18. Xue L, Salimi M, Panse I, Mjosberg JM, McKenzie AN, Spits H, Klenerman P, Ogg G. Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells. J Allergy Clin Immunol. 2014;133:1184-94.
19. Pettipher R. The roles of the prostaglandin D(2) receptors DP(1) and CRTH2 in promoting allergic responses. Br J Pharmacol. 2008;153(Suppl 1):S191-9.
20. Xue L, Barrow A, Pettipher R. Interaction between prostaglandin D and chemoattractant receptor-homologous molecule expressed on TH2 cells mediates cytokine production by TH2 lymphocytes in response to activated mast cells. Clin Exp Immunol. 2009;156:126-33.
21. Iwasaki M, Nagata K, Takano S, Takahashi K, Ishii N, Ikezawa Z. Association of a new-type prostaglandin D2 receptor CRTH2 with circulating T helper 2 cells in patients with atopic dermatitis. J Invest Dermatol. 2002;119:609-16.
22. Gyles SL, Xue L, Townsend ER, Wettey F, Pettipher R. A dominant role for chemoattractant receptor-homologous molecule expressed on T helper type 2 (TH2) cells (CRTH2) in mediating chemotaxis of CRTH2+ CD4+ TH2 lymphocytes in response to mast cell supernatants. Immunology. 2006;119:362-8.
23. Pettipher R, Hansel TT. Antagonists of the prostaglandin D2 receptor CRTH2. Drug News Perspect. 2008;21:317-22.
24. Liu H, Zheng M, Qiao J, Dang Y, Zhang P, Jin X. Role of prostaglandin D2/CRTH2 pathway on asthma exacerbation induced by Aspergillus fumigatus. Immunology. 2014;142:78-88.
25. Hall IP, Fowler AV, Gupta A, Tetzlaff K, Nivens MC, Sarno M, Finnigan HA, Bateman ED, Rand Sutherland E. Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment. Pulm Pharmacol Ther. 2015;32:37-44.
26. Uller L, Mathiesen JM, Alenmyr L, Korsgren M, Ulven T, Hogberg T, Andersson G, Persson CG, Kostenis E. Antagonism of the prostaglandin D2 receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation. Resp Res. 2007;8:16.
27. Strasser DS, Farine H, Holdener M, Zisowsky J, Roscher R, Hoerner J, Gehin M, Sidharta PN, Dingemanse J, Groenen P. Development of a decision-making biomarker for CRTH2 antagonism in clinical studies. N Horiz Transl Med. 2015;2:118-25.
28. Krug N, Gupta A, Badorrek P, Koenen R, Mueller M, Pivovarova A, Hilbert J, Wetzel K, Hohlfeld JM, Wood C. Efficacy of the oral chemoattractant receptor homologous molecule on TH2 cells antagonist BI 671800 in patients with seasonal allergic rhinitis. J Allergy Clin Immunol. 2014;133:414-9.
29. Horak F, Zieglmayer P, Zieglmayer R, Lemell P, Collins LP, Hunter MG, Steiner J, Lewis T, Payton MA, Perkins CM, et al. The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo-controlled, double-blind trial. Allergy. 2012;67:1572-9.
30. Gonem S, Berair R, Singapuri A, Hartley R, Laurencin M, Bacher G, Lu C, Holzhauer B, Bourne M, Mistry V, et al. Phase 2a randomized placebo-controlled trial of the oral prostaglandin D2 receptor (DP2/ CRTH2) antagonist QAW039 in eosinophilic asthma. Eur Respir J. 2014;44:2908.
31. Erpenbeck VJ, Salapatek AM, Patel P, Sanni J, Dubois G, Zhou P, Perry S, Larbig M. Efficacy and safety of 10 day treatment with the CRTH2 antagonist QAV680 evaluated in patients with allergic rhinitis in an environmental exposure chamber. Eur Resp J. 2014;44:P4075.
32. Sandham DA, Arnold N, Aschauer H, Bala K, Barker L, Brown L, Brown Z, Budd D, Cox B, Docx C, et al. Discovery and characterization of NVP-QAV680, a potent and selective CRTH2 receptor antagonist suitable for clinical testing in allergic diseases. Bioorg Med Chem. 2013;21:6582-91.
33. Fretz H, Valdenaire A, Pothier J, Hilpert K, Gnerre C, Peter O, Leroy X, Riederer MA. Identification of 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1 h-pyrido[4,3-b]indol-5(2 h)-yl)acetic acid (setipiprant/ACT-129968), a potent, selective, and orally bioavailable chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2) antagonist. J Med Chem. 2013;56:4899-911.
34. Sidharta PN, Diamant Z, Dingemanse J. Single- and multiple-dose tolerability and pharmacokinetics of the CRTH2 antagonist setipiprant in healthy male subjects. Fundam Clin Pharmacol. 2014;28:690-9.
35. Hoch M, Wank J, Kluge I, Wagner-Redeker W, Dingemanse J. Disposition and metabolism of setipiprant, a selective oral CRTH2 antagonist, in humans. Drugs RD. 2013;13:253-69.
36. Baldoni D, Mackie A, Gutierrez M, Theodor R, Dingemanse J. Setipiprant, a selective oral antagonist of human CRTH2: relative bioavailability of a capsule and a tablet formulation in healthy female and male subjects. Clin Ther. 2013;35:1842-8.
37. Diamant Z, Sidharta PN, Singh D, O'Connor BJ, Zuiker R, Leaker BR, Silkey M, Dingemanse J. Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics. Clin Exp Allergy. 2014;44:1044-52.
38. Santanello NC, DeMuro-Mercon C, Shah SR, Schenkel EJ, Ratner PH, Dass SB, Norquist JM, Philip G. Validation of the nighttime symptoms score as a clinically relevant measure of allergic rhinitis. Allergy Asthma Proc. 2006;27:231-9.
39. Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Validation of the standardized version of the rhinoconjunctivitis quality of life questionnaire. J Allergy Clin Immunol. 1999;104:364-9.
40. Bretz F, Pinheiro JC, Branson M. Combining multiple comparisons and modeling techniques in dose-response studies. Biometrics. 2005;61:738-48.
41. Bornkamp B, Pinheiro JC, Bretz F. MCPMOD-an R package for the design and analysis of dose-finding studies. J Stat Soft. 2009;29:1-23.
42. Krause A, Zisowsky J, Strasser DS, Gehin M, Sidharta PN, Groenen PMA, Dingemanse J. Pharmacokinetic/pharmacodynamic modelling of receptor internalization with CRTH2 antagonists to optimize dose selection. Clin Pharmacokinet. 2016;55:813-21.
43. Gehin M, Strasser DS, Zisowsky J, Farine H, Groenen PM, Dingemanse J, Sidharta PN. A novel CRTH2 antagonist: single- and multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ACT-453859 in healthy subjects. J Clin Pharmacol. 2015;55:787-97.
44. Erpenbeck VJ, Salapatek AM, Patel P, Carew D, Dubois G, Perry S, Larbig M. QAV680, cetirizine and their combination reduce nasal symptoms in patients with intermittent allergic rhinitis in an environmental exposure chamber. Eur Resp J. 2014;44(Suppl 58):P4069.
45. European Medicines Association (EMEA). Guideline on the development of medicinal products for the treatment of allergic rhinoconjunctivitis. 2004. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003554.pdf. Accessed 7 Oct 2016.
46. Curran MP, Scott LJ, Perry CM. Cetirizine: a review of its use in allergic disorders. Drugs. 2004;64:523-61.